Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study of Subretinal Administration of OpCT-001 Photoreceptor Precursor Cells Derived From iPSCs in Patients With Primary Photoreceptor Disease

NCT06789445 is registered in ClinicalTrials.gov with BlueRock Therapeutics as lead sponsor.

NCT NCT06789445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06789445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study of Subretinal Administration of OpCT-001 Photoreceptor Precursor Cells Derived From iPSCs in Patients With Primary Photoreceptor Disease
Lead sponsor
BlueRock Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 10, 2025
Completion date
October 31, 2030
Enrollment
54 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cone-rod disease (c-rd), cone-rod dystrophy, inherited retinal disease (ird), primary photoreceptor disease, retinal degeneration, retinitis pigmentosa (rp), rod-cone disease, rod-cone dystrophy, usher syndrome